Virological, Immunological, and Clinical Impact of Switching from Protease Inhibitors to Nevirapine or to Efavirenz in Patients with Human Immunodeficiency Virus Infection and Long-Lasting Viral Suppression

This publication has 12 references indexed in Scilit:

• Antiretroviral Treatment Simplification With Nevirapine in Protease Inhibitor–Experienced Patients With HIV-Associated Lipodystrophy
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
• Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection
  AIDS, 2000
• A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome
  AIDS, 2000
• Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults
  New England Journal of Medicine, 1999
• Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
  The Lancet, 1999
• Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine
  AIDS, 1999
• Efavirenz: shifting the HAART paradigm in adult HIV-1 infection
  Expert Opinion on Investigational Drugs, 1999
• Severe premature coronary artery disease with protease inhibitors
  The Lancet, 1998
• A Randomized, Double-blind Trial Comparing Combinations of Nevirapine, Didanosine, and Zidovudine for HIV-Infected Patients
  JAMA, 1998
• A Health Status Questionnaire Using 30 Items From The Medical Outcomes Study
  Medical Care, 1991